Cadila Pharmaceuticals expands oncology portfolio, launches Tarzed 

Tarzed is available as 440 mg injection

Cadila Pharmaceuticals has launched Trastuzumab, with the brand name Tarzed, which is a humanised monoclonal antibody, recommended in HER2 positive early breast cancer and metastatic breast cancer. It is available as 440 mg injection, the company notified via a statement.

Tarzed is considered safe and more efficacious compared to conventional treatment medicines for breast cancer, the statement further added.

breast cancer treatmentCadila PharmaceuticalsTarzed injection
Comments (0)
Add Comment